Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis

被引:3
|
作者
Avgerinos, Ioannis [1 ,2 ,5 ]
Karagiannis, Thomas [1 ,2 ]
Matthews, David R. [3 ,4 ]
Tsapas, Apostolos [1 ,2 ,4 ]
Bekiari, Eleni [1 ,2 ]
机构
[1] Aristotle Univ Thessaloniki, Med Dept 2, Clin Res & Evidence Based Med Unit, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Diabet Ctr, Med Dept 2, Thessaloniki, Greece
[3] Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England
[4] Univ Oxford, Harris Manchester Coll, Oxford, England
[5] Aristotle Univ Thessaloniki, Med Dept 2, Clin Res & Evidence Based Med Unit, Konstantinoupoleos 49, Thessaloniki 54642, Greece
来源
DIABETES OBESITY & METABOLISM | 2023年 / 25卷 / 10期
关键词
cardiovascular disease; heart failure; meta-analysis; SGLT-2; inhibitors; MANAGEMENT;
D O I
10.1111/dom.15200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To explore whether the beneficial cardiovascular (CV) effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitors is consistent with or without concurrent use of CV medications in patients with type 2 diabetes, heart failure (HF) or chronic kidney disease.Methods: We searched Medline and Embase up to September 2022 for CV outcomes trials. The primary endpoint was the composite of cardiovascular (CV) death or hospitalization for HF. Secondary outcomes included the individual components of CV death, hospitalization for HF, death from any cause, major adverse CV events or renal events, volume depletion and hyperkalaemia. We pooled hazard ratios (HRs) and risk ratios alongside 95% confidence intervals (CIs).Results: We included 12 trials comprising 83 804 patients. SGLT-2 inhibitors reduced the risk of CV death or hospitalization for HF regardless of background use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs), angiotensin receptor-neprilysin inhibitors (ARNIs), b-blockers, diuretics, mineralocorticoid receptor antagonists (MRAs), or triple combination therapy of either an ACEI/ARB plus b-blocker plus MRA, or an ARNI plus b-blocker plus MRA (HRs ranged from 0.61 to 0.83; P > .1 for each subgroup interaction). Similarly, no subgroup differences were evident for most analyses for the secondary outcomes of CV death, hospitalization for HF, all-cause mortality, major adverse CV or renal events, hyperkalaemia and volume depletion rate.Conclusions: The benefit of SGLT-2 inhibitors seems to be additive to background use of CV medications in a broad population of patients. These findings should be interpreted as hypothesis generating because most of the subgroups analysed were not prespecified.
引用
收藏
页码:3020 / 3029
页数:10
相关论文
共 50 条
  • [21] Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis
    Zou, Xinyu
    Shi, Qingyang
    Vandvik, Per Olav
    Mao, Yunhe
    Agarwal, Arnav
    Ponte, Belen
    Zeng, Xiaoxi
    Guyatt, Gordon
    Yang, Qinbo
    Luo, Xianghang
    Xu, Chang
    Fu, Ping
    Tian, Haoming
    Agoritsas, Thomas
    Li, Sheyu
    BMJ MEDICINE, 2024, 3 (01):
  • [22] Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
    Banerjee, Mainak
    Maisnam, Indira
    Pal, Rimesh
    Mukhopadhyay, Satinath
    EUROPEAN HEART JOURNAL, 2023, 44 (37) : 3686 - 3696
  • [23] Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among patients with cancer treated with anthracycline: A systematic review and meta-analysis
    Wannaphut, Chalothorn
    Wattanachayakul, Phuuwadith
    Saowapa, Sakditad
    Ponvilawan, Ben
    Tanariyakul, Manasawee
    Kewcharoen, Jakrin
    Yingchoncharoen, Pitchaporn
    Aiumtrakul, Noppawit
    Acoba, Jared David
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among cancer patients treated with anthracycline: a systematic review and meta-analysis
    Wannaphut, Chalothorn
    Wattanachayakul, Phuuwadith
    Saowapa, Sakditad
    Ponvilawan, Ben
    Tanariyakul, Manasawee
    Kewcharoen, Jakrin
    Yingchoncharoen, Pitchaporn
    Suenghataiphorn, Thanathip
    Aiumtrakul, Noppawit
    Acoba, Jared
    ECANCERMEDICALSCIENCE, 2025, 19
  • [25] Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure
    Patoulias, Dimitrios
    Papadopoulos, Christodoulos
    Kassimis, George
    Boulmpou, Aristi
    Karagiannis, Asterios
    Doumas, Michael
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 161 : 118 - 120
  • [26] Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review
    Thiruvenkatarajan, Venkatesan
    Meyer, Emily Jane
    Nanjappa, Nagesh
    Van Wijk, Roelof M.
    Jesudason, David
    BRITISH JOURNAL OF ANAESTHESIA, 2019, 123 (01) : 27 - 36
  • [27] Efficacy and safety of metformin and sodium-glucose co-transporter-2 inhibitors in adults with type 1 diabetes: A systematic review and network meta-analysis
    Zhang, Q.
    Wu, Y.
    Lu, Y.
    Fei, X.
    REVISTA CLINICA ESPANOLA, 2020, 220 (01): : 8 - 21
  • [28] Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis
    Li, Chao
    Zhou, Zien
    Neuen, Brendon L.
    Yu, Jie
    Huang, Yuli
    Young, Tamara
    Li, Jingwei
    Li, Lin
    Perkovic, Vlado
    Jardine, Meg J.
    Keay, Lisa
    Markoulli, Maria
    Rosenthal, Norm
    Capuano, George
    Yavin, Yshai
    Neal, Bruce
    Arnott, Clare
    DIABETES OBESITY & METABOLISM, 2021, 23 (01): : 252 - 257
  • [29] Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis
    Abiri, Behnaz
    Ahmadi, Amirhossein Ramezani
    Ebadinejad, Amir
    Hosseinpanah, Farhad
    Valizadeh, Majid
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (11) : 1853 - 1863
  • [30] Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials
    Haiyan Cao
    Xiaosheng Rao
    Junya Jia
    Tiekun Yan
    Dong Li
    Acta Diabetologica, 2023, 60 : 325 - 335